American International Group Inc. Acquires 9,946 Shares of Dynavax Technologies Co. (DVAX)

American International Group Inc. lifted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 32.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 40,399 shares of the biopharmaceutical company’s stock after acquiring an additional 9,946 shares during the quarter. American International Group Inc. owned 0.07% of Dynavax Technologies worth $869,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in DVAX. Vanguard Group Inc. raised its holdings in Dynavax Technologies by 14.4% during the 1st quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock valued at $10,864,000 after buying an additional 230,373 shares during the last quarter. Geode Capital Management LLC raised its holdings in Dynavax Technologies by 6.6% during the 1st quarter. Geode Capital Management LLC now owns 290,958 shares of the biopharmaceutical company’s stock valued at $1,731,000 after buying an additional 18,012 shares during the last quarter. Bank of America Corp DE raised its holdings in Dynavax Technologies by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 456 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Dynavax Technologies by 24.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after purchasing an additional 30,036 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in Dynavax Technologies by 77.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after purchasing an additional 79,141 shares in the last quarter. Hedge funds and other institutional investors own 70.54% of the company’s stock.

In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of the stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the sale, the vice president now directly owns 7,780 shares of the company’s stock, valued at approximately $144,708. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Robert Coffman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Dynavax Technologies Co. (NASDAQ:DVAX) traded down $0.30 during trading hours on Friday, hitting $15.75. 2,564,486 shares of the stock were exchanged, compared to its average volume of 1,350,000. Dynavax Technologies Co. has a 12-month low of $3.70 and a 12-month high of $24.45. The stock has a market cap of $954.39, a P/E ratio of -8.04 and a beta of 1.31.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same period in the prior year, the firm posted ($0.90) EPS. Dynavax Technologies’s revenue for the quarter was down 68.8% on a year-over-year basis. analysts predict that Dynavax Technologies Co. will post -1.72 earnings per share for the current fiscal year.

Several research analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Dynavax Technologies in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective for the company. Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, Cowen reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Dynavax Technologies currently has an average rating of “Hold” and a consensus target price of $25.17.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/13/dynavax-technologies-co-dvax-holdings-boosted-by-american-international-group-inc-updated-updated.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply